On December 19, 2025, President Trump announced that 14 of the 17 largest pharmaceutical companies have reached agreements with his administration to drastically lower drug prices in the U.S. These deals are part of a “Most Favored Nation” (MFN) policy intended to align American costs with the lowest prices paid in other developed nations.
Details of the Victory
- The Agreements: The deals cover nine newly announced companies—including Merck, Novartis, GSK, and Sanofi—joining five others (Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk) that signed earlier in 2025.
- Price Reductions: Specific medications will see massive price cuts when purchased through a new platform. For example, Gilead’s Hepatitis C drug Epclusa will drop from $24,920 to $2,425, and Sanofi’s Plavix will drop from $756 to $16.
- TrumpRx.gov: A new website, TrumpRx.gov, is scheduled to launch in January 2026 to facilitate direct-to-consumer sales at these discounted rates.
- Economic Impact: Beyond price cuts, the participating companies have pledged a combined $150 billion in new U.S. investment for manufacturing and R&D. In exchange, these companies receive a three-year exemption from tariffs.
- The Remaining Three: President Trump and administration officials noted that the final three companies—AbbVie, Johnson & Johnson, and Regeneron—are expected to visit the White House to finalize their participation after the holidays.
President Trump described the development as “the greatest victory for patient affordability in the history of American healthcare”.
